Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. - Wikidata - wikimedia - TriplyDB

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.

http://www.wikidata.org/entity/Q35893923

about

Role of Hedgehog Signaling Pathway in NASH Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy?The Natural Course of Non-Alcoholic Fatty Liver Disease Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD-A Systematic Review Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis Epigenetics in liver disease: from biology to therapeutics Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.Nonalcoholic Fatty Liver Disease: Pathophysiology and Management.Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Noninvasive predictors of fibrosis in NASH with and without cirrhosis, just as good as histology (and hepatic venous pressure gradient?).Noninvasive Markers of Fibrosis and Inflammation in Nonalcoholic Fatty Liver Disease.Limitations and opportunities of non-invasive liver stiffness measurement in children.Magnetic resonance elastography is superior to acoustic radiation force impulse for the Diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: A prospective study.Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease Nonalcoholic Steatohepatitis and Endpoints in Clinical Trials.A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis.Caspase-2 promotes obesity, the metabolic syndrome and nonalcoholic fatty liver disease.Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patients Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis.Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should do Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus.Alcohol Consumption in Concomitant Liver Disease: How Much is Too Much?Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score.Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease.Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms.Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial Hepatocyte Hypoxia Inducible Factor-1 Mediates the Development of Liver Fibrosis in a Mouse Model of Nonalcoholic Fatty Liver Disease.Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.An update on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Asia.Dietary Flavonoid Hyperoside Induces Apoptosis of Activated Human LX-2 Hepatic Stellate Cell by Suppressing Canonical NF-κB Signaling Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children.Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease.The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent.The Presence of White Matter Lesions Is Associated With the Fibrosis Severity of Nonalcoholic Fatty Liver Disease

P2860

Q26743373-AA626738-0446-4C71-A42F-0034D9386244 Q26744631-86B2A096-7ED4-4745-8BA8-FF430815153B Q26746947-96BFDDBA-3038-4BF8-8C46-DC0B375452D4 Q26751258-1E115F3D-9E54-4371-B9C7-0DBFA19211B9 Q28070408-93A021BE-B2C7-4AF1-88AF-ED94AD5C0EB7 Q28077079-0C77582F-7B44-40BC-836E-E63F55DD89C2 Q28079271-50BE4B2E-7852-46FD-9878-19C513EF0533 Q28079826-093251D8-7785-40F3-8932-8BF531BF6D8E Q30238749-2D887A7F-050F-4B12-9A83-11E28D42E8A1 Q30241387-61928B9D-5C38-48DB-B846-A3FFE663125E Q30249400-19DA15FD-5753-4D1A-BE3C-88F254E4E0FE Q30316067-8A594782-D286-43AA-A033-71AC25A7DC29 Q30355082-BE54873D-8778-4F7F-8AA7-8E7B1618317F Q30360182-1867937A-5909-4953-B3F2-BC643F6B3679 Q30364476-69FAFCEF-3BE9-4599-A15F-7DC6FAEAAA59 Q30368624-FF9E9874-6F0C-4009-B1C5-1D75A2B35F47 Q30376231-DB104992-E2EA-4F39-883F-9D88F3DC2158 Q30396916-B007F1AF-F459-47B6-B5DC-A8BCE3365AF6 Q33574413-8B0617BB-AD1C-4EB8-9122-D10E8118067E Q33586821-6A797368-2A28-4332-AB95-B9961CB87803 Q33594722-EC7C279D-3A11-4D0B-8B66-6187BB5567A1 Q33639969-CED541CF-4B53-4356-975D-78E81524B4F8 Q33716191-FE80FE7E-5729-4B33-A802-43534C418476 Q33802278-C61E0B1F-CB11-4190-A9E8-075C8B1DF103 Q33840930-6B91C9D7-16C4-4294-B078-926167FD0998 Q35932326-EA31ADDE-3B30-4D8E-BE11-CF9A27E129F1 Q35965687-83EB1311-ED0E-494B-84C5-2CD4E545EDAF Q36138443-1AF63FCB-94AF-4A90-B3D6-7E9C446AF0E4 Q36218142-60813C89-7696-493A-B5BC-7036C11EF376 Q36225138-C008A95F-9339-4546-9540-B2022DB2420A Q36234613-D353AF23-1815-4307-A69D-6BF6E6BB796F Q36279632-50840C4A-A27F-4D8D-80B8-904AA1291E4F Q36291761-78A48F75-9CBE-4B0F-B8E8-7F9EC6389389 Q36405031-00F567B4-0DCC-4208-9BCC-F10A07171846 Q36783945-EC9FF1E5-6954-4B9F-B87C-3FABC92B2631 Q36791363-B8FC4FE7-8E3A-47CA-A31B-94A976684627 Q36818351-EB976D4E-69ED-443E-BF1B-75E2BC6B5E43 Q36818830-F703A912-7CA9-401C-BBEC-C78F7408AB3E Q36833028-E73B69F9-35D5-4CEE-B435-E8D2BC690A1B Q36838110-855ACBAE-78F8-4444-A00B-09F5E6B527B7

P2860

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.

http://www.wikidata.org/entity/Q35893923

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Liver Fibrosis, but No Other H ...... alcoholic Fatty Liver Disease.

@ast

Liver Fibrosis, but No Other H ...... alcoholic Fatty Liver Disease.

@en

type

label

Liver Fibrosis, but No Other H ...... alcoholic Fatty Liver Disease.

@ast

Liver Fibrosis, but No Other H ...... alcoholic Fatty Liver Disease.

@en

prefLabel

Liver Fibrosis, but No Other H ...... alcoholic Fatty Liver Disease.

@ast

Liver Fibrosis, but No Other H ...... alcoholic Fatty Liver Disease.

@en

P1433

Q35893923-2CF38D7E-FB27-4DB4-B1FF-B52C2FD14AE9

P1476

Q35893923-97EC5B6A-DF04-49C6-8155-683A5D167196

P2093

Q35893923-01EC8178-0120-4B55-B8AB-BA52F85D76B3

Q35893923-0CBDC220-3EA3-4977-9504-5711FAF3223C

Q35893923-207E5CD2-F2CB-4FA7-A7CB-BE0456517401

Q35893923-31D4C7F0-3E2B-485E-BF6C-EAEB4F277A03

Q35893923-41ED8BFF-61B9-48A3-904E-961E38E8F214

Q35893923-7604C135-4D7C-4DAC-949E-960DBC93ED8C

Q35893923-7C1F3105-71E8-48DD-9F61-C021F5DA1910

Q35893923-83B53CC9-BFA1-434D-A4C9-2D228C3CFA59

Q35893923-C5407439-E847-4885-A1AA-3FB974190E58

Q35893923-D410694B-224C-49F4-BE9B-C8D6EF2F2815

P2860

Q35893923-0796C420-E824-4B62-8F06-20E39B7164B3

Q35893923-54572C4E-70BE-4D3C-9A9A-D5BFE6679DC9

Q35893923-5A05B0A7-D1BD-43B3-8076-2045648C5AED

Q35893923-6E58B2ED-5D95-462A-8DDF-27609B5DBBC3

Q35893923-7BD952FA-6145-4B4B-B6D0-5880A33B7191

Q35893923-853B2375-B4DA-40A7-A8E1-626513C992F5

Q35893923-96137D28-8340-485F-9FF7-CD733DC72243

Q35893923-A64E0C35-5205-4FAB-8843-A92ACA4CAACF

Q35893923-A9961394-2577-4E7D-B8DA-3D3FA0AA0610

Q35893923-AFD96324-480F-4987-B697-E35363D11AE2

P304

Q35893923-6702C5A2-8143-4FA6-AB5E-310A192E52E1

P31

Q35893923-E86D51C3-2897-410C-874A-B45671C6DD77

P356

Q35893923-4704EF78-8EFF-415E-814B-4AE9D578CE87

P407

Q35893923-1046C9EE-11FA-47A4-AF25-445F105D8008

P433

Q35893923-D3575722-91D6-46FF-9B87-09FA35CA8E4D

P478

Q35893923-E6569212-E911-456A-9031-19F1435B5066

P50

Q35893923-03D165E2-D59B-44E2-BF7E-092A3E5A40C5

P577

Q35893923-BF6F77E9-EEBA-44A4-920C-67BC5F549CEA

P698

Q35893923-D8B0B0C2-74F1-4886-AB8A-66CC7AB79049

P932

Q35893923-4F09446F-23B7-4C6B-B637-6A735E520867

P356

J.GASTRO.2015.04.043

P1433

Gastroenterology

P1476

Liver Fibrosis, but No Other H ...... alcoholic Fatty Liver Disease.

@en

P2093

Alisha Stahler

http://www.w3.org/2001/XMLSchema#string

Einar S Bjornsson

http://www.w3.org/2001/XMLSchema#string

Flemming Bendtsen

http://www.w3.org/2001/XMLSchema#string

Heather D Lafferty

http://www.w3.org/2001/XMLSchema#string

Jill C Keach

http://www.w3.org/2001/XMLSchema#string

Leon A Adams

http://www.w3.org/2001/XMLSchema#string

Paul Angulo

http://www.w3.org/2001/XMLSchema#string

Peter R Mills

http://www.w3.org/2001/XMLSchema#string

Phunchai Charatcharoenwitthaya

http://www.w3.org/2001/XMLSchema#string

Sanne Dam-Larsen

http://www.w3.org/2001/XMLSchema#string

P2860

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace

Management of hepatocellular carcinoma: An update

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

Long-term follow-up of patients with NAFLD and elevated liver enzymes

Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease.

Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease

Endpoints and clinical trial design for nonalcoholic steatohepatitis.

Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network

P304

389-97.e10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.GASTRO.2015.04.043

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

149

http://www.w3.org/2001/XMLSchema#string

P50

David E. Kleiner

P577

2015-04-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25935633

http://www.w3.org/2001/XMLSchema#string

P932

4516664

http://www.w3.org/2001/XMLSchema#string